KRAS and familial pancreatic carcinoma: NSC290956 at least manifested potent efficacy against the inhibition of KRas-mediated signaling, resulting in the dramatically reduced survival of the KRas-expressing human pancreatic cancer cell lines, including CFPAC-1 (KRasG12V), MIA PaCa-2 (KRasG12C), Capan-1 (KRasG12V), SW1990 (KRasG12T), and BxPC-3 (wild-type KRas) with IC50 ranging 19.7–74.2 μM.